KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Invested Capital (2016 - 2025)

CRISPR Therapeutics AG's Return on Invested Capital history spans 10 years, with the latest figure at 0.35% for Q4 2025.

  • For Q4 2025, Return on Invested Capital fell 13.0% year-over-year to 0.35%; the TTM value through Dec 2025 reached 0.35%, down 13.0%, while the annual FY2025 figure was 0.35%, 13.0% down from the prior year.
  • Return on Invested Capital for Q4 2025 was 0.35% at CRISPR Therapeutics AG, down from 0.33% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.2% in Q2 2021 and bottomed at 0.35% in Q4 2022.
  • The 5-year median for Return on Invested Capital is 0.22% (2021), against an average of 0.17%.
  • The largest annual shift saw Return on Invested Capital skyrocketed 39bps in 2021 before it tumbled -50bps in 2022.
  • A 5-year view of Return on Invested Capital shows it stood at 0.15% in 2021, then tumbled by -331bps to 0.35% in 2022, then soared by 69bps to 0.11% in 2023, then tumbled by -98bps to 0.22% in 2024, then tumbled by -60bps to 0.35% in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Return on Invested Capital are 0.35% (Q4 2025), 0.33% (Q3 2025), and 0.34% (Q2 2025).